Byetta (Amylin) is EU approved for use with basal insulin in Type 2 Diabetes patients

The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) from Amylin/Eli Lilly as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of Type 2 Diabetes in adults who have not achieved adequate glycemic control with these agents. From 2013 exenatide products will be marketed exclusively by Amylin which may seek a new partner for marketing outside the USA. see Buse JB, Bergenstal RM, Glass LC, et al. "Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial." Ann Intern Med. 2011;154:103-112.